https://www.selleckchem.com/products/ldk378.html
The median follow-up time was 22.1 months. The 3-year overall survival (OS) and 3-year progression-free survival (PFS) were 77.8% and 83.3%, respectively. One patient of definitive radiotherapy and one patient of postoperative radiation died due to distant metastasis of cervical cancer. Grade 3 or higher acute and chronic reactions occurred in 58.3% and 8.3% patients, respectively. Acute grade 3 or higher toxicity correlated with the presence of chemotherapy ( = 0.045). Modern radiotherapy for cervical cancer was well tolerated in SLE pa
Curtir
Comentario
Compartilhar
